Summary of Bioventus Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $158 million, a 3% increase year-over-year; organic growth was 10%.

Adjusted EBITDA: $37 million, up $8 million (30% increase) from the prior year, with an adjusted EBITDA margin of 23%, expanding by 490 basis points.

Adjusted Earnings per Share: $0.24 for the quarter.

Cash Flow from Operations: $38 million, nearly double compared to Q4 2024, contributing to a full-year cash flow of nearly $75 million, achieving a 92% increase year-over-year.

Debt: $94 million outstanding, with a net leverage ratio below 2.5 times, down from previous levels.

2Strategic Updates and Business Highlights

Bioventus is transitioning into a new phase focused on accelerating revenue growth while enhancing profitability and cash flow.

The company reported strong performance in its pain treatments and restorative therapies segments, with notable growth from its Duralane product.

New growth drivers include Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP), both receiving positive feedback from pilot launches.

The company plans to invest approximately $13 million in growth drivers, particularly in PNS and Ultrasonics, to drive future growth.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected net sales between $600 million and $610 million, with growth anticipated to accelerate in the second half of the year.

Earnings Guidance: Adjusted earnings per share projected at $0.73 to $0.77, indicating growth that outpaces revenue growth.

Cash Flow Guidance: Expected cash from operations to range between $82 million and $87 million, a 10% to 17% increase.

The company aims to maintain an EBITDA margin of approximately 20% for 2026.

4Bad News, Challenges, or Points of Concern

International Segment Performance: Revenue was unchanged year-over-year, indicating challenges in distributor order timing.

Restorative Therapies Decline: Revenue declined 26% due to the divestiture of the Advanced Rehabilitation business, although organic growth was 10% when excluding this impact.

Market Dynamics: The company anticipates a deceleration in organic growth in the first half of 2026, influenced by fewer selling days and inventory normalization.

5Notable Q&A Insights

Management acknowledged that the strong Q4 performance was aided by favorable order timing and selling days, which may not be sustainable into Q1 2026.

The PNS pilot launch provided valuable insights, confirming the technology's differentiation and ease of use, which will guide aggressive scaling in 2026.

The company reaffirmed expectations for a minimum 200 basis points of growth contribution from PNS and PRP combined in 2026.

Ultrasonics is a key focus area, with plans to expand sales and marketing efforts to enhance awareness and adoption. Overall, Bioventus Inc. demonstrated strong financial performance in Q4 2025, setting a solid foundation for growth in 2026 while navigating some challenges in specific segments and market dynamics.